Table 3

Summary of intraoperative indices

Intraoperative indicesStudies (n)Sample sizeRR (CI)WMD (CI)I2 (%)  P of χ2 Selected modelP for overall effect
Anti-VEGF groupNo anti-VEGF group
Duration of surgery7 (overall)111107NA–18.277 (–29.287 to –7.267)90.200.01Random-effect0.001
5 (bevacizumab)7874NA– 23.858 (–28.198 to –19.518)45.2>0.1Fixed-effect<0.05
1 (conbercept)1818NA–10.000 (–15.916 to –4.084)Fixed-effect<0.05
1 (ranibizumab)1515NA12.000 (4.038 to 19.962)Fixed-effect>0.05
Intraoperative bleeding51581450.531 (0.440 to 0.642)NA92.20.001Random-effect0.001
Frequency of required endodiathermy101721650.212 (0.126 to 0.362)–1.297 (–1.590 to –1.004)<50>0.1Fixed-effect0.001
Intraoperative iatrogenic retinal breaks6 (overall)1301280.422 (0.156 to 1.145)NA60.70.02Random-effect0.09
4 (bevacizumab)97950.351 (0.149 to 0.781)NA00.451Fixed-effect<0.05
1 (conbercept)18180.143 (0.008 to 2.581)NAFixed-effect>0.05
1 (ranibizumab)15150.806 (0.613 to 1.060)NAFixed-effect>0.05
Frequency of required relaxing retinotomy51041040.378 (0.154 to 0.929)NA00.769Fixed-effect0.034
Rate of endotamponade with silicone oil71341280.430 (0.188 to 0.981)NA69.10.002Random-effect0.045
  • NA, not available;  RR, relative risk; VEGF, vascular endothelial growth factor; WMD, weighted mean difference.